we have established a highly efficient method to purify active recombinant human m-calpain using an E. coli expression system at low temperature (22°C). This was achieved by co-expressing CAPN2 with a C-terminal histidine-tag, and CAPNS1, lacking the first Gly-repeated region at the N-terminal. After 3 sequential passes through a chromatographic column, approximately 5 mg of human m-calpain was homogenously purified from 1liter of E. coli culture. Proteins were stable for several months. This is the first report of efficient, large-scale purification of recombinant human m-calpain using an E. coli expression system.
Introduction
Calpain (Clan CA-C2, EC 3.4.22.17) belongs to a family of intracellular Ca 2+ -regulated cysteine proteases, whose members share homology in the protease domain in almost all eukaryotes and a few bacteria. In the human genome, there are 15 calpain genes with ubiquitous or tissue-specific expression. Calpains play pivotal roles in biological processes, including the cell cycle, apoptosis, and myoblast fusion, through the limited proteolytic cleavage of diverse substrates, although their physiological functions remain obscure. A number of pathological conditions, including muscular dystrophies, lissencephaly, cataracts, neurodegenerative disorders, and gastric ulcers have been associated with aberrant calpain action (1, 2) .
Two representative mammalian calpains, -and m-calpain, are ubiquitously expressed and have been extensively characterized. Both -and m-calpain exist as heterodimers, comprising the distinct 80-kDa catalytic subunits CAPN1 and CAPN2, respectively, and a common 30-kDa regulatory subunit, CAPNS1, and require M and mM levels of Ca 2+ , respectively, for their activation in vitro. CAPN1 and CAPN2 consist of a regulatory N-terminal anchor helix, followed by a protease CysPc domain, a C2-like Ca 2+ /phospholipid-binding C2L domain and a penta-EF-hand PEF domain. CAPNS1 comprises a structurally flexible, Gly-rich GR domain containing two Gly-repeated regions, and a PEF domain (Fig. 1) . The PEF domains of the catalytic and regulatory subunits interact with each other through their C-terminal EF-hand motifs, forming a heterodimer. In the absence of Ca 2+ , -and m-calpains are catalytically inactive, because the CysPC domain is separated into two protease core domains, PC1 and PC2, preventing active site formation. The binding of Ca 2+ to the PC1, PC2, C2L, and PEF domains, induces structural changes that allow the domains to form a single protease core, involving subunit dissociation and/or N-terminal autolysis in both subunits including degradation within the GR domain (3-6).
Large-scale systems in E. coli or insect cells have been used to purify full-length or truncated, recombinant -and m-calpain for structural-functional studies, involving 3D analyses. However, a persistent problem has been that recombinant full-length calpains, including -and m-calpain, aggregate as insoluble inclusion bodies within E.coli cells. In terms of large-scale purification of recombinant full-length calpain, using an E. coli expression system, this method has only been successful for rat m-calpain, by co-expression of CAPN2 and CAPNS1 lacking the GR domain at 30 o C using compatible expression vectors (7, 8) . Recombinant human m-calpain can be extracted as a soluble protein using insect cells, but it accumulates as an insoluble inclusion body in E. coli cells (9) . In this study, we have established a method for high-level expression and purification of human m-calpain in a soluble and active form, using an E. coli system at a low temperature.
Materials and methods

Reagents and antibodies
Chemical reagents were purchased from Sigma Inc. (MO, USA), Wako Pure chemicals Inc.
(Osaka, Japan), Kanto chemicals Inc. (Tokyo, Japan), and Nakarai Tesque Inc. (Kyoto, Japan).
Anti-His rabbit polyclonal antibody and anti-CAPNS1 mouse monoclonal antibody (clone P1)
were purchased from Santa Cruz Biotechnology Inc. (CA, USA) and American Type Culture Collection (VA, USA), respectively.
Expression vectors
The cDNAs encoding human CAPN2, CAPNS1, CAPNS1G1, and CAPNS1G2 (for structures, see The pACpET24 vector contains an ampicillin-resistant gene, the T7 promoter, and the A15 replication origin.
Protein expression and purification
CAPN2/pET was co-transformed into E. coli BL21(DE3) (Novagen) with CAPNS1/pACpET, CAPNS1G1/pACpET, or CAPNS1G2/pACpET, and the transformants were stored as frozen glycerol stocks at -80°C. For protein expression and purification, frozen transformants were precultured at 27°C overnight, in 30 ml of LB medium containing 100 g/ml ampicillin and 50 
Activity assay for calpain
The proteolytic activity of calpain was measured using casein (Sigma), as previously described, with some modifications (10) . Aliquots of the fractions eluted from columns were incubated at 30°C for 20 min, in reaction buffer (100 mM Tris-Cl (pH 7.5), 3 mg/ml casein, and 20 mM 2-mercaptoethanol) with 5 mM CaCl 2 or 5 mM EDTA, in total volume of 50 l. After incubation, the reactions were stopped by the addition of 150 l of 7% (v/v) trichloroacetic acid, incubated on ice for 30 min, and centrifuged at 15,000 rpm for 15 min at 4°C. A 280 of the supernatant was measured using a spectrophotometer (SmartSpec-3000, Bio-Rad Laboratories Inc., CA, USA). One unit of calpain caseinolytic activity was defined as a Ca 2+ -dependent increase in A 280 of 1.0, in 1-hour, in a 1-ml scale reaction. The proteolytic activity was also measured using a fluorogenic substrate, succynyl-Leu-Leu-Val-Tyr-4-methylcoumaryl-7-amide (Suc-LLVY-MCA) (Peptide Institute Inc., Osaka, Japan), with some modifications (11). The final peak fraction was incubated with 10-500 mM substrate for 10 min at 30°C, in 100 mM Tris-Cl (pH 7.5), 5 mM CaCl 2 , 20 mM -mercaptoethanol, and 0.2% 
Casein zymography
Casein zymography was performed as previously described (12) . Two g of the final peak fraction, 1 g of recombinant human m-calpain purified by Sf9/vaculovirus expression system, and 25 g of non-transfected COS7 cell lysate were added to Native-PAGE loading buffer (250 mM Tris-Cl, pH 6.8, 50% glycerol, 1 mM DTT, and 0.005% bromophenol blue), and run on a 12% polyacrylamide gel containing 2mg/ml casein at 125 V for 3 h. After electrophoresis, the gel was incubated overnight in Ca 2+ incubation buffer (50 mM Tris-Cl, pH 7.0, 5 mM CaCl 2 , and 10 mM DTT), stained with Coomassie Brilliant Blue (CBB) R250, and destained with destain solution (10% acetic acid and 30% methanol).
SDS-PAGE and western blotting
SDS-PAGE was performed as previously described (13) . Samples were added to SDS-PAGE loading buffer (62 mM Tris-Cl (pH 6.8), 143 mM 2-mercaptoethanol, 2% SDS, 0.005% bromophenol blue, and 10% glycerol), boiled for 5 min, and analyzed on 10 or 12% polyacrylamide gels. The gels were stained with CBB R250. For western blotting, proteins were subjected to SDS-PAGE, transferred to PVDF membranes (Immobilon-P, Millipore Inc., MA, USA), and probed with appropriate antibodies. Signals were detected using a POD immunostain 9 kit (Wako Pure Chemicals Inc.).
Results and Discussion
Expression of recombinant human m-calpain
It was previously reported that fully active, recombinant rat m-calpain was successfully produced at 30 o C by bacterial co-expression of CAPN2 with a C-terminal His-tag, and 21K, CAPNS1 lacking the N-terminal GR domain (amino acid (aa) 1-86) and using the two compatible expression vectors, pET24b(+) and pACpET24, with distinct antibiotic-resistant genes, and replicons (7, 8) . We applied this strategy to human m-calpain, although it was reported that, in E. coli cells, recombinant human m-calpain formed inclusion bodies that could not be renatured (9) .
When CAPN2/pET and CAPNS1/pACpET were used in bacterial co-expression, expression levels of CAPNS1 were very low, and the CAPN2 protein was almost insoluble under the tested conditions ( Figs. 2A and 2B ). After DEAE column chromatography, the soluble lysate gave CAPN2-enriched, but not active fractions (data not shown). This suggests that the two Gly repeat regions in the GR domain caused a deleterious interaction with the host's post-translational machinery, as in the case of recombinant rat m-calpain containing full-length CAPNS1 (8) . Therefore, instead of a CAPNS1/pACpET construct, we used truncated forms of CAPNS1, CAPNS1G1/pACpET and CAPNS1G2/pACpET. As shown in Fig. 1 , CAPNS1G1/pACpET lacks one Gly repeat (aa 1-25), while CAPNS1G2/pACpET lacks both Gly repeats (aa 1-58), in the GR domain. As a result, the yields and solubility of not only CAPNS1G1 and CAPNS1G2 but also CAPN2 showed similar improvement at a lower growth temperature (22°C), after adding IPTG. In addition, the C-terminal His-tag fused to CAPN2 was not truncated during protein expression ( Figs. 2A and 2B ). We therefore co-expressed CAPNS1G1, the closest to native form, with CAPN2, for large-scale 11 purification.
Purification of recombinant human m-calpain
As described in Material and Methods, purification of co-expressed CAPN2+CAPNS1G1 was performed by sequential column chromatography, using DEAE-Toyopearl, HisTrap, and MonoQ columns. At each column step, the eluted fractions were monitored for calpain activity by caseinolytic assay. Calpain activity was detected in the fractions containing 200-250 mM NaCl from the DEAE column, 50-125 mM imidazole from the HisTrap column, and 450 mM NaCl from the MonoQ column. SDS-PAGE analysis of the peak active fractions eluted from each column, indicates that CAPN2 and CAPNS1G1 were co-eluted and almost homogeneously purified (Fig. 2C) . The final preparation gave a clear band at the same position as a control sample in casein zymography (Fig. 2D) . Gel filtration analysis of the final preparation showed a single elution peak at a position estimated to be 110 kDa, which is almost identical to theoretical total molecular weight of CAPN2 with the His-tag and CAPNS1G1 (Fig. 3) . These results indicate that CAPN2 and CAPNS1G1 formed a heterodimer without high molecular weight aggregates or dissociated molecules. The results of purification are summarized in Table 1 . From 1 liter of E. coli culture, we obtained 5.8 mg of purified recombinant human m-calpain, with a yield of 51.1%, which was higher than that of recombinant human m-calpain obtained from a Sf9/baculovirus expression system (9). This protein was stable for several months. The final preparation showed a half maximal activity of approximately 0.5 mM Ca 2+ , and a specific activity of 334 U/mg for casein, and Km and Kcat values for Suc-LLVY-MCA were determined as 0.322 mM and 0.066 sec -1 , respectively (Fig. 4) .
These values are similar to those reported previously for recombinant or native m-calpain (9) (10) (11) 14) , indicating that the N-terminal 25 amino acid truncation of CAPNS1 did not affect enzymatic properties of intact calpain, such as heterodimerization, specific activity, and the Ca 2+ -requirement.
In conclusion, we have established a highly efficient bacterial expression and purification system for recombinant human m-calpain, a system that is easier to manipulate than the Sf9/baculovirus expression system. Our methodology has the potential to assist researchers with structural and physiological studies. Sustained activation of -and m-calpains is associated with various pathological states, making these proteases an obvious potential therapeutic target to reduce or prevent a spectrum of human diseases. Great efforts are underway to develop selective calpain inhibitors, and the use of human calpains rather than mammalian orthologues would be of great benefit in this process. In addition, our expression system and constructs may provide resources for further analysis into the physiological significance of the hydrophobicity exhibited by Gly-repeats in the calpain GR domain. 
